Drug Type CAR-T |
Synonyms- |
Target |
Action antagonists |
Mechanism EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma Multiforme | Phase 1 | Finland | 15 May 2020 | |
Glioblastoma Multiforme | Phase 1 | India | 15 May 2020 | |
Glioblastoma Multiforme | Phase 1 | Finland | 15 May 2020 | |
Glioblastoma Multiforme | Phase 1 | India | 15 May 2020 | |
Metastatic Malignant Neoplasm to the Leptomeninges | Phase 1 | Finland | 15 May 2020 | |
Metastatic Malignant Neoplasm to the Leptomeninges | Phase 1 | Finland | 15 May 2020 | |
Metastatic Malignant Neoplasm to the Leptomeninges | Phase 1 | India | 15 May 2020 | |
Metastatic Malignant Neoplasm to the Leptomeninges | Phase 1 | India | 15 May 2020 |